The Royal College of Ophthalmologists Guidelines on AMD: Executive Summary. - Wikidata - wikimedia - TriplyDB

The Royal College of Ophthalmologists Guidelines on AMD: Executive Summary.

The Royal College of Ophthalmologists Guidelines on AMD: Executive Summary.

http://www.wikidata.org/entity/Q37406856

about

Defining response to anti-VEGF therapies in neovascular AMD The concordance of care for age related macular degeneration with the chronic care model: a multi-centered cross-sectional study.Repeatability of Foveal Measurements Using Spectralis Optical Coherence Tomography Segmentation Software [Delayed treatment initiation of more than 2 weeks. Relevance for possible gain of visual acuity after anti-VEGF therapy under real life conditions (interim analysis of the prospective OCEAN study)].Non-responsiveness to intravitreal aflibercept treatment in neovascular age-related macular degeneration: implications of serous pigment epithelial detachment.Investigation of time to first presentation and extrahospital factors in the treatment of neovascular age-related macular degeneration: a retrospective cross-sectional study.The potential of spectral domain optical coherence tomography imaging based retinal biomarkers.

P2860

Q26996510-D8662098-DCBE-4293-B5D0-2BCBD531B252 Q34301308-E5F4CED7-61A7-4760-B7D4-AEA6ECB99C22 Q35664225-97322F3E-74A2-4468-A8E9-7777D8D94048 Q41558337-AA23DF65-708C-4751-A71C-DB7495460911 Q42426609-E4482777-72B4-4A2A-A00A-E48A10F309F5 Q47327666-F9E0BDFF-E5B5-41CC-BCFE-AF6EC721806D Q50791101-62302B76-BD04-4E3F-BD22-A125E7311BFE

P2860

The Royal College of Ophthalmologists Guidelines on AMD: Executive Summary.

http://www.wikidata.org/entity/Q37406856

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 25 October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

The Royal College of Ophthalmologists Guidelines on AMD: Executive Summary.

@en

The Royal College of Ophthalmologists Guidelines on AMD: Executive Summary.

@nl

type

label

The Royal College of Ophthalmologists Guidelines on AMD: Executive Summary.

@en

The Royal College of Ophthalmologists Guidelines on AMD: Executive Summary.

@nl

prefLabel

The Royal College of Ophthalmologists Guidelines on AMD: Executive Summary.

@en

The Royal College of Ophthalmologists Guidelines on AMD: Executive Summary.

@nl

P1433

Q37406856-27AFCC2C-BE0B-4839-8B1A-76FB67F81B23

P1476

Q37406856-F5F31527-46ED-4CBC-ABB9-3ACEEDD0C485

P2093

Q37406856-A4B25F0A-2C3F-4F5E-A475-CEF1A17CD961

P2860

Q37406856-078BF1B1-A199-4F88-8D50-54E3B006170B

Q37406856-08B974E7-79CA-4160-83DC-ABBEEBADCAF7

Q37406856-0AA513F3-CFC8-4888-AF09-B956AD946E5A

Q37406856-0B8AEE69-5652-4960-9A0D-FA608A45D7F3

Q37406856-0BA6DC65-A232-4F6C-A14B-ED2CDA157D6E

Q37406856-10542981-B4DB-4EE7-932D-9243099569F1

Q37406856-22C07933-C1E5-4498-AAEE-6DB96ECF0494

Q37406856-3CB61566-E458-4B99-959E-3C8BE2AC9768

Q37406856-60156FDF-CF67-4DC3-BAC4-119DB3C41117

Q37406856-76D2C4F4-D4C4-40C6-AF7B-4A07A0A04BD0

P2888

Q37406856-F251C752-F4DF-44FE-BFFA-315BACADA8BB

P304

Q37406856-EC15DE13-7C6D-43DC-8968-5FE369B83861

P31

Q37406856-0CA91F3E-8D70-400C-BC8D-570120DA7A8C

P356

Q37406856-B4A6CAE0-0C80-4B5F-9AB5-BFEF596AFEDA

P433

Q37406856-3BBA65A0-15AB-4A18-911B-CF289E8505C8

P478

Q37406856-F08FF024-38B6-4033-BD9A-FFB7D84508BD

P50

Q37406856-8F8BE136-8695-4803-999C-289BF540DFBB

Q37406856-ADB324BE-DA99-4EDD-A804-AA581ED26D9C

P577

Q37406856-1C457C8E-32B8-4D97-8479-252C140FD854

P5875

Q37406856-BBFA839E-E6B5-46C3-BCE5-D80D04A6C79F

P698

Q37406856-D3729FEE-544F-4681-8BEC-3D2701387375

P932

Q37406856-8385C80A-1259-4F6E-A21C-E0456EB0E5A4

P356

P1433

P1476

The Royal College of Ophthalmologists Guidelines on AMD: Executive Summary.

@en

P2093

AMD Guidelines Group

http://www.w3.org/2001/XMLSchema#string

P2860

Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration

Radiotherapy for neovascular age-related macular degeneration

Submacular surgery for choroidal neovascularisation secondary to age-related macular degeneration

A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8

Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3

Dietary antioxidants and primary prevention of age related macular degeneration: systematic review and meta-analysis

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial

Ranibizumab for neovascular age-related macular degeneration

P2888

P304

1429-1431

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/EYE.2013.233

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Usha Chakravarthy

P577

2013-10-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258043565

http://www.w3.org/2001/XMLSchema#string

P698

24158023

http://www.w3.org/2001/XMLSchema#string

P932

3869519

http://www.w3.org/2001/XMLSchema#string